Tinlarebant (LBS-008)

Name: Tinlarebant (LBS-008) in Stargardt disease type 1: Pharmacodynamics
Published: 2026-09-14T15:39:06-04:00

Stargardt disease type 1

Section

Pharmacodynamics

1 evidence topic · 2 sources

“Tinlarebant (5 mg/day, p.o.) produces a sustained mean RBP4 reduction of ~80%.” (opens the source at this quote in a new tab)